MGNX News and Press, MacroGenics Inc. From 09/22/20

MacroGenics (MGNX) announces encouraging preliminary data from a Phase 1/2 clinical trial evaluating flotetuzumab in acute myeloid leukemia ((AML)) patients. The results were just published in the journal Blood.In a subset of patients high poor prognoses and high unmet medical needs, the comp...

ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a m...

MacroGenics ([[MGNX]] -7.3%) announces clinical data from the dose escalation portion of a Phase 1 clinical trial of MGD019. The data were presented at the ESMO Virtual Congress 2020. MGD019, a bispecific PD-1 × CTLA-4 DART molecule, was designed to enhance CTLA-4 blockade on dual-e...

MacroGenics (MGNX) announced a $15M milestone payment has been triggered under its exclusive global collaboration and license agreement with Incyte for retifanlimab ((MGA012)).The milestone was triggered by the initiation of the Phase 3 POD1UM-304 clinical trial, evaluating the efficacy and s...

$15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte ROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antib...

MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibition Recommended Phase 2 dose established for MSS CRC, NSCLC expansion cohorts Presentation is available on-demand as part of the ESMO Virtual Congress 2020  ...

A 94-subject Phase 2 clinical trial, PODIUM-202 , evaluating Incyte's (NASDAQ: INCY ) PD-1 inhibitor retifanlimab (formerly INCMGA0012) in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemo showed a tr...

Image source: The Motley Fool. MacroGenics   (NASDAQ: MGNX) Q2 2020 Earnings Call Jul 30, 2020 , 4:30 p.m. ET Operator Continue reading

MacroGenics, Inc. (MGNX) Q2 2020 Earnings Conference Call July 30, 2020 04:30 PM ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President and CEO Jim Karrels - CFO Stephen Eck - CMO Conference Call Participants Debjit Chattopadhyay - H.C. Wain...

MacroGenics (NASDAQ: MGNX ) : Q2 GAAP EPS of -$0.94 misses by $0.04 . More news on: MacroGenics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...